REFERENCIAS

  1. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. 2006;332(7550):1134-1138.

  2. Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006;6:177.

  3. Graham GG1, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013;21(3):201-32.
    Ver documentación

  4. Amimi S. Osayande, and Suarna Mehulic. Diagnosis and Initial Management of Dysmenorrhea..University of Texas Southwestern Medical Center, Dallas, Texas. AAFP. Am Fam Physician.2014;89(5):341-346.
    Ver documentación

  5. Paracetamol –Monografía -Equipo de redacción de IQB (Centro colaborador de La Administración Nacional de Medicamentos, alimentos y Tecnología Médica -ANMAT-Argentina). Rv 04-2014.

  6. Marjoribanks J1, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev. 2003;(4):CD001751.
    Ver documentación

  7. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD001751.
    Ver documentación

  8. Primary Dysmenorrhea Consensus Guideline. SOGC CLINICAL PRACTICE GUIDELINE. No 169, December 2005. 1117 -1130.
    Ver documentación

Redes Sociales